Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  AUTOIMMUNE DISEASE THERAPEUTICS
A Global Strategic Business Report

This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in Millions of US$ by the following therapeutic class – Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics only), and Others. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. The report profiles 115 companies including many key and niche players worldwide such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck Serono SA, Novartis AG, Sanofi-aventis SA , Schering-Plough Corporation, Shire Pharmaceuticals Group plc, Teva Pharmaceuticals Industries Limited, and UCB Pharma. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1829  PAGES:    723
PRICE:    $3950  DATE:       July 2009
COMPANIES:  115  MARKET DATA TABLES:   283
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  AUTOIMMUNE DISEASE THERAPEUTICS (Complete Report) Pages : 723   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS4$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definition and Scope of Study.....I-3
Rheumatoid Arthritis.....I-3
  
   Multiple Sclerosis.....I-4
Psoriasis.....I-4
Crohn's disease.....I-4
  
II. EXECUTIVE SUMMARY104$2250
  1. INDUSTRY OVERVIEW & OUTLOOK.....II-13 $300  
   Autoimmune Disease Therapeutics Market Continues to Flourish.....II-1
Pharmaceutical Industry Hit by Economic Downturn.....II-1
Credit Crunch to Affect Biological Drug Pipeline.....II-1
1$100
   Biotech Bankruptcies Rife in the Current Economic Downturn.....II-2
Economic Downturn Takes Toll on R&D.....II-2
Global Market Estimates and Forecasts.....II-2
Analysis by Region.....II-2
1$100
   Analysis by Segment.....II-3
1$100
  2. MARKET DYNAMICS AND TRENDS.....II-42 $200  
   Biologics Continue to Gain Market Share.....II-4
New Products to Drive Market Growth.....II-4
Biogenerics to Expand Adoption of Biological Drugs.....II-4
1$100
   New Indications to Fuel Market Growth.....II-5
Superior Outcomes to Enhance Adoption of Biologics.....II-5
Efficacy and Convenience – Key Factors Driving Physician’s Decision.....II-5
1$100
  3. DISEASE OVERVIEW.....II-69 $900  
   Immunity and Immune System.....II-6
Autoimmune Diseases.....II-6
Women- Highly Susceptible to Autoimmune Diseases.....II-6
1$100
   Table 1: Percentage Breakdown of Incidence of Autoimmune Diseases in Men and Women (includes corresponding Graph/Chart).....II-7
Complexity in Manifestations Renders Difficulty in Understanding the
  Conditions.....II-7
1$300
   Etiology of Autoimmune Diseases.....II-8
Genetic Predisposition.....II-8
1$100
   Environmental Factors.....II-9
Autoimmune Diseases – A Social and Health Burden.....II-9
Regulatory Glitches and High Costs Hinder Biogenerics.....II-9
1$100
   Types of Autoimmune Diseases.....II-101$100
   Incidence and Prevalence.....II-11
Diagnosis and Treatment of Autoimmune Diseases.....II-11
Overview on Select Biologic Drugs.....II-11
Remicade.....II-11
1$100
   Humira.....II-12
Rituxan® (rituximab).....II-12
1$100
   Cimzia.....II-13
Cimzia to Face Stiff Competition in Rheumatoid Arthritis Market.....II-13
1$100
   Psoriasis – A Promising Market for Cimzia.....II-14
Actemra.....II-14
Enbrel.....II-14
1$100
  4. OVERVIEW OF SELECT AUTOIMMUNE DISEASES.....II-1531 $1750  
   Rheumatoid Arthritis.....II-15
Disease Overview.....II-15
Low Penetration to Sustain growth of Anti-TNF Drugs.....II-15
Incidence and Prevalence Higher in Urban and Developed Regions.....II-15
1$100
   Diagnosis.....II-16
Treatment of Rheumatoid Arthritis.....II-16
BRMs Revolutionize RA Treatment.....II-16
1$100
   Drugs Used in Treating Rheumatoid Arthritis.....II-17
Table 2: Leading Biologic Drugs for Rheumatoid Arthritis Worldwide (2007): Value Sales for Enbrel, Remicade, Humira, Orencia, Rituxan and Kineret (US$ Million).....II-17
1$300
   Year of Approval of Leading Biologics in Rheumatoid Arthritis Therapy.....II-18
Key Drugs In Late Stage Development for Rheumatoid Arthritis Treatment.....II-18
Competitive Landscape.....II-18
1$100
   Table 3: Comparative Analysis of Leading Biologic Rheumatoid Arthritis Drugs based on ACR Scores by End Point.....II-19
High Prices and Safety Concerns.....II-19
1$300
   Multiple Sclerosis.....II-20
Etiology.....II-20
Types of Multiple Sclerosis.....II-20
1$100
   Table 4: Prevalence of Different Types of Multiple Sclerosis.....II-21
Pathology.....II-21
1$300
   Prevalence of Multiple Sclerosis High in Women.....II-22
Facts About Multiple Sclerosis.....II-22
Treatment.....II-22
1$100
   Interferon Drugs - High Efficacy Drugs in Existing MS Therapies.....II-23
Beta Interferon Drugs in Multiple Sclerosis Treatment.....II-23
Non-Interferon Drugs.....II-23
1$100
   Non-Interferon Drugs in Multiple Sclerosis Treatment.....II-24
Trends in Multiple Sclerosis Market.....II-24
High Unmet Need and Rich Pipeline to Expand MS Market.....II-24
Interferon-based Drugs Lead Multiple Sclerosis Drug Market.....II-24
1$100
   Oral Drugs in Pipeline to Alter Market Dynamics in MS Therapies.....II-251$100
   Dip in Sales Inevitable for Current Therapies.....II-26
Tough Times Ahead for Betaseron.....II-26
1$100
   Competitive Landscape.....II-27 1$100
   Table 5: Leading Multiple Sclerosis Drugs Worldwide (2007) by Sales: Avonex, Rebif, Copaxone, Betaseron and Tysabri (includes corresponding Graph/Chart).....II-28

Table 6: Leading Multiple Sclerosis Drugs Worldwide (2000, 2003 and 2006): Market Shares for Avonex, Rebif, Copaxone, Betaseron and Tysabri (includes corresponding Graph/Chart).....II-28
1$300
   Multiple Sclerosis Drug Pipeline – An Overview.....II-29
Drugs Under Development for Treating Multiple Sclerosis.....II-29
FTY 720 (Fingolimod).....II-29
Mylinax.....II-29
1$100
   Laquinimod.....II-30
Campath (Alemtuzumab) - Trials Marred with Side Effects.....II-30
1$100
   Teriflunomide.....II-31
Fampridine-SR.....II-31
BG-12 (Oral Fumarate).....II-31
MN-166.....II-31
1$100
   Psoriasis.....II-32
Prevalence.....II-32
Available Treatment Options.....II-32
1$100
   Biological Drugs Lead the Fray.....II-33
Table 7: Leading Psoriasis Drugs Worldwide (2005): Market Share by Value Sales for Biologics (Enbrel, Raptiva and Amevive), Systemic Drugs, and Topicals (includes corresponding Graph/Chart).....II-33
1$300
   Inflammatory Bowel Diseases.....II-34
Crohn's disease.....II-34
Stages of the Disease.....II-34
Prevalence.....II-34
Diagnosis.....II-34
1$100
   Treatment.....II-351$100
   Global Crohn’s Disease Therapeutics Market: Leading Biological Drugs and their
  Worldwide.....II-36
Year of Approval for Leading Drugs in Crohn’s Disease Treatment.....II-36
Ulcerative Colitis.....II-36
Diagnosis and Treatment.....II-36
1$100
   Other Diseases.....II-37
Systemic Lupus Erythematosus (SLE).....II-37
Prevalence and Epidemiology.....II-37
Treatment.....II-37
1$100
   Sjogren's Syndrome.....II-381$100
   Prevalence and Epidemiology.....II-39
Diagnosis and Treatment.....II-39
Type-1 Diabetes Mellitus.....II-39
1$100
   Types of Diabetes Mellitus.....II-40
Type 1 or Insulin Dependent Diabetes Mellitus.....II-40
Type 2 or Non-Insulin Dependent Diabetes Mellitus.....II-40
Insulin – Vital for Blood Glucose Management.....II-40
Etiology.....II-40
1$100
   Prevalence.....II-41
Diabetes in Children - A Growing Concern.....II-41
Diagnosis and Treatment.....II-41
1$100
   Autoimmune Hepatitis.....II-42
Disease Categories.....II-42
Treatment.....II-42
Side Effects.....II-42
1$100
   Juvenile Rheumatoid Arthritis.....II-43
Symptoms.....II-43
Diagnosis.....II-43
Scleroderma.....II-43
1$100
   Prevalence.....II-44
Etiology.....II-44
Diagnosis.....II-44
Management.....II-44
Vasculitis Syndeomes.....II-44
1$100
   Haematologic Autoimmune Diseases.....II-45
Ankylosing Spondylitis.....II-45
1$100
  5. PRODUCT INTRODUCTIONS/APPROVALS.....II-466 $400  
   Cimzia® Receives FDA Approval for Treating Rheumatoid Arthritis.....II-46
Simponi™ Receives FDA Approval for Treating Rheumatoid Arthritis.....II-46
HUMIRA® Obtains EU Approval for Polyarticular Juvenile Idiopathic Arthritis.....II-46
1$100
   Cimzia® Receives FDA Nod for Treating Crohn’s Disease.....II-47
HUMIRA® Obtains Approval from Japanese Ministry for Rheumatoid Arthritis.....II-47
HUMIRA® Receives FDA Clerance for Polyarticular Juvenile Idiopathic Arthritis.....II-47
Abbott Receives EU Marketing Authorization for Humira in Psoriasis Treatment.....II-47
1$100
   Xian-Janssen Introduces Remicade, Branded infliximab in China.....II-48
HUMIRA® Obtains EU Approval for Treating Crohn’s Disease.....II-48
HUMIRA® Obtains FDA Approval for Crohn’s Disease.....II-48
Remicade® Obtains Approval for Use in PsA and Early RA in Australia.....II-48
1$100
   Tysabri™ Receives Health Canada Approval for Use in Multiple Sclerosis.....II-49
Rituxan® Gets FDA Approval for Use in RA.....II-49
Humira® Obtains FDA Approval for Treating AS.....II-49
1$100
   Betaseron® Receives FDA Approval for Use in First Clinical Episode of MS.....II-50
Abbott Receives FDA Clearance for HUMIRA Pen.....II-50
Remicade Obtains FDA Approval for Treating Pediatric Crohn`s Disease.....II-50
2$200
  6. RECENT INDUSTRY ACTIVITY.....II-5226 $1400  
   Novo Nordisk and VLST Collaborate on Therapeutic Targets Development.....II-52
Actemra’s Approval Gets Delayed.....II-52
1$100
   Apitope Raises Financing for Developing Multiple Sclerosis Compound.....II-53
CalciMedica to Acquire Rights to STIM1 from TorreyPines.....II-53
1$100
   Roche Acquires ARIUS Research, Inc......II-54
Astellas Inks Agreement with Maxygen for MAXY-4 Candidates.....II-54
1$100
   Carna and Caliper Life Sciences Ink Collaborative Supply Agreement.....II-55
Isotechnika Gets Back Worldwide Rights to Transplant Drug, Voclosporin.....II-55
1$100
   Boehringer In-licenses Two Drug Targets from BioFocus.....II-56
Bionomics Enters into a Development and Licensing Agreement with Merck Serono.....II-56
1$100
   Nycomed Inks Agreement with Immunomedics for Veltuzumab.....II-57
EpiVax Receives Grants from National Institutes of Health to Advance Epi-13.....II-57
1$100
   Boehringer to Takeover Actimis.....II-58
Antisoma Acquires Xanthus Pharmaceuticals.....II-58
1$100
   Merrimack Acquires Funds for Developing Cancer and Autoimmune Disease
  Biologics.....II-59
BioSeek and Merck Sign Collaboration Agreement for Compound Evaluation.....II-59
Questcor Amends Distribution Contract with US Distributor of Acthar.....II-59
1$100
   ANP Completes Phase IIa Trial for Multiple Sclerosis Drug.....II-60
Insert and Calando Merge to Form Calando Pharmaceuticals.....II-60
Codon Inks Research & Development and Licensing Deal with Merrimack.....II-60
1$100
   Debiopharm Inks licensing Deal with Airmid for Debio 0824 ShK Peptide.....II-61
Chelsea Acquires Global Rights to I-3D Range of DHODH Inhibiting Compounds.....II-61
1$100
   Cypress Bioscience Acquires Proprius.....II-62
J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals.....II-62
GlaxoSmithKline Acquires License to Market Vaccinex’s Antibody.....II-62
Teva to Takeover CoGenesys.....II-62
1$100
   Hadasit, HMS and BWH to Co-develop Oral Therapy for Autoimmune Diseases.....II-63
Anthera Acquires Rights to Develop and Market AMG 623 from Amgen.....II-63
Can-Fite Enters into Two Cooperation Agreements to Develop CF102 Drug.....II-63
Source MDx Inks an Agreement with Pfizer.....II-63
1$100
   Cambridge Inks an Antibody Development Agreement with Medarex.....II-64
Pfizer to Acquire Coley Pharma.....II-64
GSK Joins Hands with Tolerx to Develop and Commercialize otelixizumab.....II-64
1$100
   Amgen Acquires Avidia.....II-651$100
   Eli Lilly and MacroGenics Tie Up for Developing Teplizumab.....II-66
MorphoSys and Genesis Ink Antibody R&D Deal.....II-66
1$100
   arGentis Enters into a License Agreement with UTRF.....II-67
Eden Biodesign to Investigate Novel Drug Candidate for Autoimmune Diseases.....II-67
Nuon and Kissei Team up for Tranilast.....II-67
1$100
   Organon and Dyax Team Up for Developing Therapeutic Antibodies.....II-68
Medarex Joins Hands with Mitsubishi for Monoclonal Antibody Development.....II-68
Merck and Archemix Collaborate.....II-68
1$100
   Genzyme Takes Over Bioenvision.....II-69
Organon and Medarex Ink Drug Development Deal.....II-69
CalciMedica Secures Exclusive Rights for CBR’s Autoimmune Drug Target.....II-69
1$100
   Xanthus Secures Exclusive Patent Estate Rights for FLT3 Pathway.....II-70
Eisai Corporation Acquires Morphotek.....II-70
1$100
   TIRC Changes Name to Orchestra Therapeutics.....II-71
Abbott Files HUMIRA® for Psoriasis in the US and EU (USA/Europe).....II-71
Accentia Secures Exclusive Global Rights to Revimmune.....II-71
1$100
   Medarex and Compugen Ink Collaborative Agreement for Therapeutic Antibody.....II-721$100
   SRI and Telik Sign License Agreement for Drug Development.....II-73
China Biopharma Signs Agreement with Chinese Biopharmaceutical Firm.....II-73
1$100
   Kirin and Astellas Ink Licensing Agreement for Anti-CD40 Antagonistic mAb.....II-74
QSV and Artielle Sign Contract to Produce RTL-1000.....II-74
1$100
   JDRF and MacroGenics Form Partnership.....II-75
GSK and Genmad Sign Partnership Agreement for HuMaxCD20.....II-75
1$100
   Biocon Enters into Joint Venture Agreement with Neopharma.....II-76
Pipex Pharmaceuticals Acquires Remaining Stake in Effective Pharmaceuticals.....II-76
1$100
   Astellas Acquires Worldwide Rights for Amevive®.....II-77
Biogen Acquires Fumapharm.....II-77
Biogen and UCB Join Hands for Oral Multiple Sclerosis Therapy.....II-77
1$100
  7. FOCUS ON SELECT GLOBAL PLAYERS.....II-7815 $1000  
   Abbott Laboratories (USA).....II-78
Amgen Inc. (USA).....II-78
1$100
   Bayer Schering Pharma AG (Germany).....II-791$100
   Biogen Idec Inc. (USA).....II-801$100
   Bristol-Myers Squibb Company (USA).....II-811$100
   Elan Corporation, plc (Ireland).....II-821$100
   Eli Lilly And Company (USA).....II-83
F. Hoffmann-La Roche AG (Switzerland).....II-83
1$100
   Chugai Pharmaceutical Co., Ltd. (Japan).....II-841$100
   Genentech, Inc. (USA).....II-851$100
   GlaxoSmithKline Plc (UK).....II-861$100
   Johnson & Johnson, Inc. (USA).....II-871$100
   Merck Serono SA (Switzerland).....II-88
Novartis AG (Switzerland).....II-88
1$100
   Sanofi-aventis SA (France).....II-891$100
   Schering-Plough Corporation (USA).....II-90
Shire Pharmaceuticals Group Plc (Ireland).....II-90
1$100
   Teva Pharmaceuticals Industries Limited (Israel).....II-911$100
   UCB Pharma (Belgium).....II-92
1$100
  8. GLOBAL MARKET PERSPECTIVE.....II-93   
   Table 8: World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-931$300
   Table 9: World 10-year Perspective for Autoimmune Disease Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-941$300
   Table 10: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-951$300
   Table 11: World 10-year Perspective for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-961$300
   Table 12: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-971$300
   Table 13: World 10-year Perspective for Multiple Sclerosis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-981$300
   Table 14: World Recent Past, Current & Future Analysis for Psoriasis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-991$300
   Table 15: World 10-year Perspective for Psoriasis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1001$300
   Table 16: World Recent Past, Current & Future Analysis for Crohn’s Disease Therapeutics (Biologics) by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-1011$300
   Table 17: World 10-year Perspective for Crohn’s Disease Therapeutics (Biologics) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1021$300
   Table 18: World Recent Past, Current & Future Analysis for Other Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-1031$300
   Table 19: World 10-year Perspective for Other Autoimmune Disease Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1041$300
III. MARKET66$1950
  1. THE UNITED STATES.....III-137 $1675  
   A. Market Analysis.....III-1
Current and Future Analysis.....III-1
Autoimmune Diseases Fact Sheet.....III-1
1$75
   Table 20: Prevalence of Key Autoimmune Diseases in the US for 2006 (in Millions) (includes corresponding Graph/Chart).....III-2
Market Trends.....III-2
Biologic Drugs Lead the Fray.....III-2
Biologics To Add Further Impetus to the Market.....III-2
1$150
   Rheumatoid Arthritis Drugs Lead the Market.....III-3
Enbrel and Humira Continue to Gain Share in the Anti-TNF Market.....III-3
Increased Incidence and Rise in Drug Prices to Drive Growth in MS Market.....III-3
1$75
   Table 21: US Multiple Sclerosis Drug Market (2006): Percentage Breakdown of Number of Dispensed Prescriptions for Avonex, Copaxone, Rebif, Betaseron and Tysabri (includes corresponding Graph/Chart).....III-4
Incidence of Type 1 Diabetes Mellitus Endemic in White Youth.....III-4
Lialda’s Share Gaining Momentum in Ulcerative Colitis Drugs Market.....III-4
1$150
   Key Ulcerative Colitis Drugs Market in the US (2006).....III-5
Table 22: US Ulcerative Colitis Drugs Market (2007 & 2008): Percentage Breakdown of Prescriptions Dispensed Ranked by Leading Drugs for Asacol, Pentasa, Lialda, Canasa, Sulphasalazine, Colazal, Other Drugs and Generics (includes corresponding Graph/Chart).....III-5
1$150
   Product Launches/ Approvals.....III-63$225
   Strategic Corporate Developments.....III-919$825
   Key Players.....III-288$350
   B. Market Analytics.....III-36
Table 23: US Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-36
1$150
   Table 24: US 10-year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-37
1$150
  2. JAPAN.....III-383 $300  
   A. Market Analysis.....III-38
Current and Future Analysis.....III-38
Product Launches/Approvals.....III-38
Key Players.....III-38
1$75
   B. Market Analytics.....III-39
Table 25: Japanese Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-39
1$150
   Table 26: Japanese 10-year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics), and Other Autoimmune Diseases for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-40
1$150
  3. EUROPE.....III-4116 $850  
   A. Market Analysis.....III-41
Current and Future Analysis.....III-41
Europe – A Burgeoning Market for Autoimmune Disease Therapeutics.....III-41
Increasing Awareness to Drive Market Growth.....III-41
Low Penetration to Fuel Growth in European MS DMDs Market.....III-41
1$75
   Table 27: Prevalence of Key Autoimmune Diseases in Europe for 2006 in Millions (includes corresponding Graph/Chart).....III-42
Lower Treatment Rate Bodes Huge Potential for the UK MS Drug Market.....III-42
Drugs Hindering Disease Progression to Gain Prominence.....III-42
1$150
   Product Launches/Approvals.....III-431$75
   Strategic Corporate Developments.....III-443$225
   Key Players.....III-478$400
   B. Market Analytics.....III-55
Table 28: European Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-55
1$150
   Table 29: European 10-year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-56
1$150
  4. REST OF WORLD.....III-5710 $775  
   A. Market Analysis.....III-57
Current and Future Analysis.....III-57
Canada.....III-57
Canada – Highest Prevalence Rates for Multiple Sclerosis.....III-57
Sales of Biologics on the Rise in Canadian Rheumatoid Arthritis Drugs
  Market.....III-57
1$75
   Asia-Pacific.....III-58
Autoimmune Diseases Market in Asia-Pacific – An Overview.....III-58
Incidence of Multiple Sclerosis in India on the Rise.....III-58
1$75
   Overview of Rheumatoid Arthritis in Australia.....III-59
Table 30: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Age Group (includes corresponding Graph/Chart).....III-59
1$150
   Table 31: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Sex (includes corresponding Graph/Chart).....III-60
Overview of Irritable Bowel Diseases in Australia.....III-60
1$150
   Product Launches/Approvals.....III-611$75
   Strategic Corporate Developments.....III-623$225
   B. Market Analytics.....III-65
Table 32: Rest of World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis(Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-65
1$150
   Table 33: Rest of World 10-year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-661$150
IV. COMPETITIVE LANDSCAPE 531$995
  
Total Companies Profiled: 115 (including Divisions/Subsidiaries - 122)

Region/Country                 Players


The United States                77
Canada                            9
Japan                             2 
Europe                           26 
     France                       1
     Germany                      6
     The United Kingdom           7
     Rest of Europe              12 
Asia-Pacific (Excluding Japan)    8
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.